Advancing Cardiac Care: AI in Aortic Stenosis Management

By HEOR Staff Writer

May 10, 2024

AI in Aortic Stenosis Management

Introduction

The specialty of cardiac care is constantly evolving, and artificial intelligence (AI) has emerged as a formidable advocate in this environment. Its integration into the management of aortic stenosis (AS), a prevalent cardiac ailment, is transforming patient outcomes. A study developed an AI model, the Digital AS Severity index (DASSi), that demonstrated excellent performance for the discrimination of severe AS across 9338 studies in 3 distinct cohorts.

AI-Driven Diagnostics: A Game-Changer in Cardiac Health

The traditional approach to diagnosing and monitoring AS relies heavily on Doppler echocardiography. However, this method faces challenges due to the heterogeneity of AS and its variable progression rates. With AI, specifically the DASSi, we are now in possession of a tool that is not constrained by these limitations. The DASSi, developed through a deep learning strategy, analyses echocardiographic videos to predict severe AS with remarkable accuracy. This self-supervised, contrastive learning model has proven effective across diverse cohorts, indicating its robustness and adaptability.

Personalised Patient Care Through AI

Personalised healthcare is the cornerstone of modern medicine. DASSi’s ability to stratify AS risk among patients with early-stage disease exemplifies this personalised approach. It aids clinicians in identifying individuals likely to experience rapid disease progression, ensuring timely intervention. The AI model’s predictive capability remains strong, regardless of traditional Doppler parameters, highlighting its potential to individualise patient care pathways.

Cross-Modal Validation: A Testament to AI’s Versatility

The versatility of DASSi is further evidenced by its successful application across different imaging modalities. By translating echocardiographic data to align with cardiac magnetic resonance (CMR) imaging, DASSi maintains its diagnostic integrity. This cross-modal validation is not just a technical triumph but also a step towards more inclusive, accessible cardiac screening.

The Prospects of Artificial Intelligence in Cardiac Imaging

AI has the potential to fundamentally alter cardiac imaging, which is a promising prospect for the future. DASSi’s validation across multinational cohorts and imaging modalities underscores its potential as a universal tool for AS assessment. Its deployment in various clinical settings, without the need for protocol modifications, positions it as a key instrument in the global fight against heart disease.

Conclusion

AI’s integration into cardiac care, particularly for AS management, offers a glimpse into a future where precision medicine is the norm. The DASSi provides a good example of the transforming power of AI, providing clinicians with a potent tool for early detection and risk stratification of AS. We are getting closer to a world in which cardiovascular care can be monitored with an unprecedented level of precision and foresight as we become more open to these technological breakthroughs.

Reference url

Recent Posts

GBA-PD therapy development
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion

By João L. Carapinha

May 26, 2026

Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
menstrual health monitoring
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...
Perioperative Bladder Cancer Therapy
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen

By João L. Carapinha

May 25, 2026

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of KEYTRUDA (pembrolizumab), including its subcutaneous formulation KEYTRUDA SC, combined with Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment followed b...